In EGFR-mutant cancer cells, an oncogenic mutation in the catalytic subunit alpha of phosphatidylinositol-4,5-bisphosphate 3-kinase (PIK3CA) was adequate to induce resistance to gefitinib, an EGFR inhibitor. Here, EGFR is linked to cancer.